MEK inhibition impairs influenza B virus propagation without emergence of resistant variants
Stephan Ludwig1, Thorsten Wolff, Christina Ehrhardt
1Robert-Koch Institut, D-13353 Berlin, Germany. stephan.ludwig@uni-duesseldorf.de
Abstract:
Influenza A and B viruses are still a major worldwide threat. We demonstrate that influenza B virus infection induces signaling via the Raf/MEK/ERK cascade, a process required for efficient virus production. Expression of dominant-negative Raf and ERK mutants or treatment with a MEK inhibitor (U0126) strongly impaired viral propagation, while selective activation of the pathway resulted in increased virus titers. MEK inhibition appears to interfere with a distinct viral nuclear export process. Most importantly, no resistant virus variants emerged in the presence of U0126 demonstrating that influenza viruses cannot easily adapt to the missing cellular function.
Insights
Influenza B virus infection relies on the Raf/MEK/ERK pathway for replication. Inhibiting this pathway with U0126 blocks viral spread and nuclear export, with no resistant strains emerging.
Area of Science:
- Virology
- Molecular Biology
- Cellular Signaling
Background:
- Influenza viruses, particularly types A and B, pose a significant global health risk.
- Understanding host-pathogen interactions is crucial for developing effective antiviral strategies.
Purpose of the Study:
- To investigate the role of the Raf/MEK/ERK signaling cascade in influenza B virus replication.
- To determine if targeting this pathway can inhibit viral propagation and assess the potential for resistance development.
Main Methods:
- Utilized dominant-negative mutants of Raf and ERK.
- Employed the MEK inhibitor U0126 to block the Raf/MEK/ERK pathway.
- Assessed viral propagation and titers in response to pathway modulation.
Main Results:
- Influenza B virus infection activates the Raf/MEK/ERK cascade, which is essential for efficient virus production.
- Inhibition of MEK (using U0126) or expression of dominant-negative mutants significantly impaired viral propagation.
- Selective activation of the pathway led to increased virus titers.
- MEK inhibition was found to interfere with a specific viral nuclear export process.
- Crucially, no resistant influenza virus variants emerged when treated with U0126, indicating limited adaptability to this host-directed therapy.
Conclusions:
- The Raf/MEK/ERK signaling pathway is a critical host factor supporting influenza B virus replication.
- Targeting this pathway, specifically MEK, represents a promising antiviral strategy with a low risk of resistance.
- This host-directed approach highlights the potential for developing novel therapeutics against influenza viruses.
Related Concept Videos
Inhibitors Of Virion Release
Leaky Scanning
Influenza
Inhibitors of Viral Protein Synthesis


